Bevacizumab: The phoenix of breast oncology?

The Lancet Oncology

Volumn 16, Issue 6, 2015, Pages 600-601

  Andre, Fabrice ^a,b   Deluche, Elise ^a   Bonnefoi, Herve ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Universite Paris Sud   (France)

^c INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; BREAST NEOPLASMS; FEMALE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; TAXOIDS;

EID: 84930275346     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70201-9     Document Type: Note

References (9)

1. Miles DW, Diéras V, Cortés J, Duenne A-A, Yi J, O'Shaughnessy J First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013, 24:2773-2780.
2. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 2014, 25:1871-1888.
3. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013, 14:933-942.
4. Earl HM, Hiller L, Dunn JA, et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol 2015, published online May 12. http://dx.doi.org/10.1016/S1470-2045(15)70137-3.
5. Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012, 366:310-320.
6. Von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012, 366:299-309.
7. Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015, 33:13-21.
8. Jubb AM, Harris AL Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010, 11:1172-1183.
9. Elamin YY, Rafee S, Toomey S, Hennessy BT Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron 2014, published online Oct 18. 10.1007/s12307-014-0160-8.